The FDA announced today that it approved Samsung Bioepis’ Byooviz injection, making it the first approved biosimilar to Lucentis for treating eye diseases.
Byooviz (ranibizumab-nuna), the first biosimilar to Lucentis (ranibizumab injection), treats several eye diseases and conditions, including neovascular (wet) age-related macular degeneration (nAMD). The treatment is administered by intravitreal injection (delivered into the vitreous humor of the eye) once a month.
Get the full story at our sister site, Drug Delivery Business News.